Endoscopic Evaluation of PET/CT Abnormalities in the Gastrointestinal Tract: Yield and Approach.
18F-fluorodeoxyglucose
Endoscopy
Gastrointestinal neoplasm
Hematologic malignancy
PET/CT
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
16 Dec 2023
16 Dec 2023
Historique:
received:
19
07
2023
accepted:
04
12
2023
medline:
17
12
2023
pubmed:
17
12
2023
entrez:
16
12
2023
Statut:
aheadofprint
Résumé
Unexpected hypermetabolic activity is often encountered in the gastrointestinal tract when PET/CT is performed for various indications, prompting endoscopic evaluation. Our aim was to characterize the types of lesions seen in segments of the gastrointestinal tract with unexpected PET/CT abnormalities as well as clinically significant lesions seen on endoscopy which did not produce a PET/CT abnormality to guide the endoscopist tasked with evaluating these imaging findings. We retrospectively reviewed a database of endoscopies performed at City of Hope Comprehensive Cancer Center between January 1, 2016 and September 30, 2021 for an indication of "abnormal PET." We divided the gastrointestinal tract into segments and defined categories of endoscopic/histologic findings for each segment. We counted the number of segments with an abnormal PET/CT finding and corresponding endoscopic/histologic abnormality as well as the number of segments with an endoscopic/histologic abnormality but normal PET/CT. PET/CT identified 209 segments with hypermetabolic activity, 109 of which had corresponding endoscopic/histologic abnormalities. In the jejunum and ileum, all corresponding lesions were malignant. Seventy-three percent of corresponding lesions in the stomach were H. pylori positive. PET/CT failed to detect 34.7% of clinically significant lesions diagnosed endoscopically, including 1 malignancy in the transverse colon and many inflammatory or low-risk premalignant lesions. PET/CT abnormalities seen in the small bowel should be evaluated urgently as nearly all correlates were malignant, while abnormalities in the stomach should prompt workup for H. pylori. Most lesions missed by PET/CT were inflammatory or low-risk premalignant yet clinically significant, confirming the need to inspect the entirety of the upper or lower gastrointestinal tract during endoscopy.
Sections du résumé
BACKGROUND
BACKGROUND
Unexpected hypermetabolic activity is often encountered in the gastrointestinal tract when PET/CT is performed for various indications, prompting endoscopic evaluation. Our aim was to characterize the types of lesions seen in segments of the gastrointestinal tract with unexpected PET/CT abnormalities as well as clinically significant lesions seen on endoscopy which did not produce a PET/CT abnormality to guide the endoscopist tasked with evaluating these imaging findings.
METHODS
METHODS
We retrospectively reviewed a database of endoscopies performed at City of Hope Comprehensive Cancer Center between January 1, 2016 and September 30, 2021 for an indication of "abnormal PET." We divided the gastrointestinal tract into segments and defined categories of endoscopic/histologic findings for each segment. We counted the number of segments with an abnormal PET/CT finding and corresponding endoscopic/histologic abnormality as well as the number of segments with an endoscopic/histologic abnormality but normal PET/CT.
RESULTS
RESULTS
PET/CT identified 209 segments with hypermetabolic activity, 109 of which had corresponding endoscopic/histologic abnormalities. In the jejunum and ileum, all corresponding lesions were malignant. Seventy-three percent of corresponding lesions in the stomach were H. pylori positive. PET/CT failed to detect 34.7% of clinically significant lesions diagnosed endoscopically, including 1 malignancy in the transverse colon and many inflammatory or low-risk premalignant lesions.
CONCLUSION
CONCLUSIONS
PET/CT abnormalities seen in the small bowel should be evaluated urgently as nearly all correlates were malignant, while abnormalities in the stomach should prompt workup for H. pylori. Most lesions missed by PET/CT were inflammatory or low-risk premalignant yet clinically significant, confirming the need to inspect the entirety of the upper or lower gastrointestinal tract during endoscopy.
Identifiants
pubmed: 38104053
doi: 10.1007/s10620-023-08231-6
pii: 10.1007/s10620-023-08231-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Kamel EM, Thumshirn M, Truninger K, Schiesser M, Fried M, Padberg B, Schneiter D, Stoeckli SJ, von Schulthess GK, Stumpe KD. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 2004;45:1804–1810.
pubmed: 15534047
Israel O, Yefremov N, Bar-Shalom R, Kagana O, Frenkel A, Keidar Z, Fischer D. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med 2005;46:758–762.
pubmed: 15872347
Ravizza D, Bartolomei M, Santoro L, Tamayo D, Fiori G, Trovato C, De Cicco C, De Roberto G, Paganelli G, Crosta C. Positron emission tomography for the detection of colorectal adenomas. Dig Liver Dis 2010;42:185–190.
doi: 10.1016/j.dld.2009.06.018
pubmed: 19643688
Luboldt W, Volker T, Wiedemann B, Zophel K, Wehrmann U, Koch A, Toussaint T, Abolmaali N, Middendorp M, Aust D et al. Detection of relevant colonic neoplasms with PET/CT: promising accuracy with minimal CT dose and a standardised PET cut-off. Eur Radiol 2010;20:2274–2285.
doi: 10.1007/s00330-010-1772-0
pubmed: 20503051
pmcid: 2914265
Weston BR, Iyer RB, Qiao W, Lee JH, Bresalier RS, Ross WA. Ability of integrated positron emission and computed tomography to detect significant colonic pathology: the experience of a tertiary cancer center. Cancer 2010;116:1454–1461.
doi: 10.1002/cncr.24885
pubmed: 20143447
Kei PL, Vikram R, Yeung HW, Stroehlein JR, Macapinlac HA. Incidental finding of focal FDG uptake in the bowel during PET/CT: CT features and correlation with histopathologic results. AJR Am J Roentgenol 2010;194:W401-406.
doi: 10.2214/AJR.09.3703
pubmed: 20410385
Gutman F, Alberini JL, Wartski M, Vilain D, Le Stanc E, Sarandi F, Corone C, Tainturier C, Pecking AP. Incidental colonic focal lesions detected by FDG PET/CT. AJR Am J Roentgenol 2005;185:495–500.
doi: 10.2214/ajr.185.2.01850495
pubmed: 16037527
Goldin E, Mahamid M, Koslowsky B, Shteingart S, Dubner Y, Lalazar G, Wengrower D. Unexpected FDG-PET uptake in the gastrointestinal tract: endoscopic and histopathological correlations. World J Gastroenterol 2014;20:4377–4381.
doi: 10.3748/wjg.v20.i15.4377
pubmed: 24764676
pmcid: 3989974
Hosni MN, Kassas M, Itani MI, Rahal MA, Al-Zakleet S, El-Jebai M, Abi-Ghanem AS, Moukaddam H, Haidar M, Vinjamuri S et al: The Clinical Significance of Incidental GIT Uptake on PET/CT: Radiologic, Endoscopic, and Pathologic Correlation. Diagnostics (Basel) 2023, 13.
Gilhotra RA, Song L, Remedios M, Malacova E, Appleyard M, Ryan K, Grimpen F. Clinical significance of incidental (18) FDG PET uptake in the gastrointestinal tract: a retrospective cohort study. Intern Med J 2023;53:1670–1677.
doi: 10.1111/imj.16002
pubmed: 36565444
Kousgaard SJ, Gade M, Petersen LJ, Thorlacius-Ussing O. Incidental detection of colorectal lesions on (18) F-FDG-PET/CT is associated with high proportion of malignancy: A study in 549 patients. Endosc Int Open 2020;8:E1725–E1731.
doi: 10.1055/a-1266-3308
pubmed: 33269303
pmcid: 7671755
Pandit-Taskar N, Schoder H, Gonen M, Larson SM, Yeung HW. Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET. AJR Am J Roentgenol 2004;183:1143–1147.
doi: 10.2214/ajr.183.4.1831143
pubmed: 15385321
Valente MA. Endoscopic and histopathological analysis of incidental focal colorectal. Am J Surg 2018;215(3):379–381.
doi: 10.1016/j.amjsurg.2017.11.010
pubmed: 29195691
van Kouwen MC, Nagengast FM, Jansen JB, Oyen WJ, Drenth JP. 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol 2005;23:3713–3717.
doi: 10.1200/JCO.2005.02.401
pubmed: 15923568
Esmer AC, Oksuzoglu K, Sen F, Yazici H, Tazeoglu D, Ergelen R, Ones T, Yegen SC. Evaluation of Colonoscopic Results of Patients with Incidental Colonic FDG Uptake in PET/CT Imaging. World J Surg 2023;47:2532–2541.
doi: 10.1007/s00268-023-07135-w
pubmed: 37516690
Kobayashi S, Ogura M, Suzawa N, Horiki N, Katsurahara M, Ogura T, Sakuma H: 18F-FDG uptake in the stomach on screening PET/CT: value for predicting Helicobacter pylori infection and chronic atrophic gastritis. BMC Medical Imaging 2016, 16.
Cronin CG, Swords R, Truong MT, Viswanathan C, Rohren E, Giles FJ, O’Dwyer M, Bruzzi JF. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol 2010;194:W91–W103.
doi: 10.2214/AJR.09.2637
pubmed: 20028897
Skrypets T, Ferrari C, Nassi L, Margiotta Casaluci G, Puccini B, Mannelli L, Filonenko K, Kryachok I, Clemente F, Vegliante MC et al: 18F-FDG PET/CT Cannot Substitute Endoscopy in the Staging of Gastrointestinal Involvement in Mantle Cell Lymphoma. A Retrospective Multi-Center Cohort Analysis. J Pers Med 2021, 11.
Albano D, Ferro P, Bosio G, Fallanca F, Re A, Tucci A, Maria Ferreri AJ, Angelillo P, Gianolli L, Giubbini R et al. Diagnostic and Clinical Impact of Staging (18)F-FDG PET/CT in Mantle-Cell Lymphoma: A Two-Center Experience. Clin Lymphoma Myeloma Leuk 2019;19:e457–e464.
doi: 10.1016/j.clml.2019.04.016
pubmed: 31129112
Schuster DM, Nanni C, Fanti S, Oka S, Okudaira H, Inoue Y, Sorensen J, Owenius R, Choyke P, Turkbey B et al. Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med 2014;55:1986–1992.
doi: 10.2967/jnumed.114.143628
pubmed: 25453047